Moreover, the use of immune checkpoint inhibitors like anti-PD-1 and anti-PD-L1 monoclonal antibodies has been successfully applied in different cancers like liver cancer and lung cancer, melanoma and Hodgkin’s lymphoma [82,83,84]. Here, PDCD1 is linked to melanoma.